Overview

Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema

Status:
Completed
Trial end date:
2018-12-28
Target enrollment:
0
Participant gender:
All
Summary
prospective study evaluating the impact of subthreshold micropulsed laser on the number of Aflibercept injections when used as an adjuvant therapy in eyes with diabetic macular edema.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Al Hadi Hospital
Treatments:
Aflibercept
Criteria
Inclusion Criteria:

- older than 18 years old

- diagnosed with DME with central macular thickness (CMT) more than 250 µm measured by
OCT

- best corrected visual acuity (BCVA) between 20/400 and 20/40.

Exclusion Criteria:

- patients with intra-ocular surgery as cataract surgery within 6 months

- prior intravitreal injection of any drug within the preceding 6 months

- panretinal photocoagulation (PRP) within the former 4 months.

- Patients with previous macular laser

- patients with vitreo-macular traction (VMT) syndrome

- severe glaucoma

- other retinal vascular diseases

- conditions that impede the OCT interpretation